23andme and its user data will soon belong to the pharmaceutical giant

23ndme will continue to provide customer DNA testing services after purchasing them from bankruptcy. The New York -based biotechnology company Regeneron Pharmaceuticals The agreement was announced on Monday To purchase the startup of 23andme for $ 256 million, along with the total health and research services and the vital lamp for customer data and genetic samples.

Regeneron is the winner of the 23DME bankruptcy auction, who requires all offers of offers to comply with the applicable laws and company privacy policies on customer data. 23ndme says that the customer’s unknown data and the stored genetic samples are destroyed when Users delete their 23ndme accountsBut it is not clear how much information is kept, and therefore, it may be close to Regeneron.

The acquisition is expected to be closed later this year, according to the approval of the US Banking Court. If everything goes, the co -founder of Regeneron George D. Yancopoulos says that the purchase will enhance the company’s “extensive genetic research” in the company in medicines and future treatments.

23ndme has collected samples and genetic data from more than 15 million customers since the launch of the DNA testing group at home. Once shortly for $ 6 billion after its launch in 2021, the company It was submitted for bankruptcy in March After failing to make profit. The co -founder and former CEO, Ann Wujiki, stepped in the same time from the company.

“We are pleased to reach a treatment that increases the value of work and enables the 23DME mission to live, while maintaining critical protection on the customer’s privacy, choice and approval in relation to their genetic data.” “We are grateful to Regeneron to provide work for all employees of the acquired business units, which will allow us to continue our mission of helping people understand the health benefits, understand and gain them through a greater understanding of the human genome.”